Werfen completed the acquisition of Omixon for $25m.

Werfen, family-owned innovative company focused on specialized diagnostics, completed the acquisition of Omixon, a global transplantation diagnostic company, for $25m. “I am proud of Omixon’s innovative products and achievements in transplant diagnostics. Joining Werfen marks an exciting new chapter, enabling us to expand our global reach and enhance our innovative solutions. Together, we will better serve the transplant community worldwide,” Attila Bérces, Omixon Founder and CEO.